CA2845884A1 - Clostridium difficile antibodies - Google Patents

Clostridium difficile antibodies Download PDF

Info

Publication number
CA2845884A1
CA2845884A1 CA2845884A CA2845884A CA2845884A1 CA 2845884 A1 CA2845884 A1 CA 2845884A1 CA 2845884 A CA2845884 A CA 2845884A CA 2845884 A CA2845884 A CA 2845884A CA 2845884 A1 CA2845884 A1 CA 2845884A1
Authority
CA
Canada
Prior art keywords
antibody
antigen
amino acid
binding portion
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2845884A
Other languages
English (en)
French (fr)
Inventor
Jody Berry
Darrell JOHNSTONE
Joyee Antony George
Bonnie TIGHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biosolutions Canada Inc
Original Assignee
Cangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cangene Corp filed Critical Cangene Corp
Publication of CA2845884A1 publication Critical patent/CA2845884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2845884A 2011-08-22 2012-08-22 Clostridium difficile antibodies Abandoned CA2845884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526031P 2011-08-22 2011-08-22
US61/526,031 2011-08-22
PCT/US2012/051948 WO2013028810A1 (en) 2011-08-22 2012-08-22 Clostridium difficile antibodies

Publications (1)

Publication Number Publication Date
CA2845884A1 true CA2845884A1 (en) 2013-02-28

Family

ID=47746848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2845884A Abandoned CA2845884A1 (en) 2011-08-22 2012-08-22 Clostridium difficile antibodies

Country Status (10)

Country Link
US (2) US9505847B2 (cg-RX-API-DMAC7.html)
EP (1) EP2748194A4 (cg-RX-API-DMAC7.html)
JP (1) JP6281163B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140078633A (cg-RX-API-DMAC7.html)
CN (1) CN103917559B (cg-RX-API-DMAC7.html)
AU (2) AU2012298877B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004162A2 (cg-RX-API-DMAC7.html)
CA (1) CA2845884A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201400916XA (cg-RX-API-DMAC7.html)
WO (1) WO2013028810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400916XA (en) * 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
PL2822967T3 (pl) 2012-03-09 2020-01-31 Csl Behring Ag Kompozycje zawierające immunoglobuliny typu wydzielniczego
AU2013352034B2 (en) * 2012-11-28 2018-08-02 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
US20170065702A1 (en) * 2014-02-19 2017-03-09 Cangene Corporation Methods of modulating an immune response
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
IL262726B2 (en) 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
CN111263769B (zh) * 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN112661849B (zh) * 2020-12-17 2022-05-20 杭州贤至生物科技有限公司 一种艰难梭菌重组蛋白单克隆抗体的制备方法和应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
ES2533492T3 (es) 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US7790203B2 (en) 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP2500362A3 (en) * 2007-11-13 2012-10-24 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against TL1A
JP5848863B2 (ja) * 2008-01-11 2016-01-27 国立大学法人 東京大学 抗ｃｌｄｎ６抗体
US7740844B2 (en) * 2008-04-29 2010-06-22 Taiwan Liposome Co. Ltd Anti-VEGF monoclonal antibody
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
BR112012026021B1 (pt) 2010-04-15 2022-05-03 Progenics Pharmaceuticals, Inc Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão
SG11201400916XA (en) * 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies

Also Published As

Publication number Publication date
KR20140078633A (ko) 2014-06-25
US9505847B2 (en) 2016-11-29
CN103917559A (zh) 2014-07-09
JP6281163B2 (ja) 2018-02-21
AU2012298877B2 (en) 2018-01-04
EP2748194A4 (en) 2015-01-28
CN103917559B (zh) 2018-01-12
JP2014529610A (ja) 2014-11-13
HK1199886A1 (en) 2015-07-24
NZ622798A (en) 2016-09-30
US9994630B2 (en) 2018-06-12
US20170051047A1 (en) 2017-02-23
AU2018202199A1 (en) 2018-04-26
BR112014004162A2 (pt) 2018-04-24
SG10201804809RA (en) 2018-07-30
WO2013028810A1 (en) 2013-02-28
SG11201400916XA (en) 2014-06-27
AU2012298877A1 (en) 2014-03-13
EP2748194A1 (en) 2014-07-02
US20140004118A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
US9994630B2 (en) Clostridium difficile antibodies
AU2011239470B2 (en) Antibodies for the treatment of Clostridium difficile-associated infection and disease
AU2018241107B2 (en) Antibodies to s. aureus surface determinants
US10117933B2 (en) Antibodies against Clostridium difficile
CN104203976A (zh) 艰难梭状芽孢杆菌毒素的人源抗体
NZ622798B2 (en) Clostridium difficile antibodies
HK1199886B (en) Clostridium difficile antibodies
RU2630663C2 (ru) Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
HK1179982A (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
HK1179982B (en) Antibodies for the treatment of clostridium difficile-associated infection and disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170818

FZDE Dead

Effective date: 20200831